Kisspeptin-10

Kisspeptin-10 is a peptide fragment consisting of 10 amino acids derived from the larger kisspeptin protein, which plays a critical role in the regulation of reproductive hormone secretion. It is an endogenous ligand for the G-protein-coupled receptor GPR54, also known as Kiss1R, and is involved in activating signaling pathways that influence endocrine and reproductive functions.

The kisspeptin system was originally identified for its role in suppressing metastasis in melanoma cells, but subsequent research revealed its fundamental importance in controlling the hypothalamic-pituitary-gonadal axis. Kisspeptin-10 represents a bioactive peptide fragment of this system, widely used in laboratory research to elucidate kisspeptin’s mechanisms and physiological effects.

In preclinical studies, Kisspeptin-10 has been investigated for its influence on hormone levels such as luteinizing hormone, follicle-stimulating hormone, and testosterone, as well as its emerging role in bone metabolism and cellular senescence. Due to its rapid metabolism and short half-life, research also focuses on understanding its degradation pathways and stability to optimize detection and experimental use.

Researchers study Kisspeptin-10 to better understand its potential therapeutic targets in reproductive endocrinology, bone resorption disorders, and degenerative joint diseases, although it remains a research chemical and is not approved for clinical use.

Research on Kisspeptin-10 encompasses its endocrine, skeletal, and cellular protective roles. A 2024 study validated a urine testing method for Kisspeptin-10 using liquid chromatography-mass spectrometry, addressing its rapid metabolism and identifying key metabolites to improve detection sensitivity. This work is critical for both research integrity and doping control.

Another 2024 investigation elucidated the molecular mechanism by which Kisspeptin-10 prevents bone loss. By binding to GPR54 on osteoclasts, Kisspeptin-10 upregulates Dusp18, which dephosphorylates Src kinase, thereby inhibiting osteoclast hyperactivity and mitigating bone resorption. Knockout mouse models further confirmed the pathway’s physiological relevance.

A 2025 study explored Kisspeptin-10’s role in protecting chondrocytes from TNF-α-induced senescence, a key factor in osteoarthritis pathology. The peptide restored SIRT1 levels and suppressed the p53/p21 signaling pathway, reducing cellular senescence markers and enhancing telomerase activity. This suggests potential utility in preserving cartilage health in degenerative joint disease models.

Research involving Kisspeptin-10 typically utilizes nanomolar-range concentrations in in vitro experiments to study cellular signaling and receptor activation. For example, concentrations of 50 to 100 nM have been employed to assess effects on chondrocyte senescence and hormone release in cultured cells. In vivo dosing protocols vary widely depending on the animal model and experimental design, with precise dosing regimens not yet standardized in the literature.

Due to its rapid metabolism and short half-life observed in preclinical models, dosing frequency and delivery methods are important considerations in experimental setups. Researchers often account for these pharmacokinetic properties when designing studies, although comprehensive dose-response characterizations remain limited. Thus, dosing information should be interpreted strictly within the context of controlled laboratory research without implication for clinical use.